- A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Oral LB20304 (Gemifloxacin) at Doses of 160mg or 320mg (Equivalent to 200mg or 400mg of the Mesylate Salt) Once Daily for 7 Days for the Treatment of Acute Exacerbations of Chronic Bronchitis (AECB) in Korean Adult Population
-
Kim YW, Shim YS, Kim WD, Shim TS, Kang HM, Choi BW, Kim JY, Kwon OJ, Kim H, Kim JO, Jung KS, Hyeon IG, Mo EK, Lee SJ, Nam GH, Lee KY, Park JS
- KMID: 1970546
- Tuberc Respir Dis.
- 2003 Jul;55(1):69-87.
- doi: 10.4046/trd.2003.55.1.69
BACKGROUND: LB20304(gemifloxacin) is a new fluoroquinolone antibacterial agent with excellent activity against both Gram-negative and Gram-positive organisms. In vitro studies using clinical isolates have shown gemifloxacin to be highly active... -
- CITED
-
- Close
- SHARE
-
- Close
